Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Care Continues To Draw Top Venture Dollars

This article was originally published in PharmAsia News

Executive Summary

Financial consulting firm ChinaVenture has published a Q1 2008 report on China's venture investment, which shows health care continues to be the hot favorite for investors. Capital injected in the industry reached $83.99 million in the quarter, 55.6 percent up over the same year-ago period. The proportion of funds channeled into health care by project number increased from 9.7 percent in Q1 2006 to 12.5 percent in Q4 2007; the percentage of total capital climbed from 10.4 percent to 22.3 percent over the same period. The number of health care programs invested in 2007 jumped to 32 from 19 the previous year; the $303 million attracted was 309.5 percent more than 2006. ChinaVenture believes that China's health reform policies and potential market are encouraging more funds into the industry, making it a key investment area. (Click here for more - Chinese language)

You may also be interested in...



Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

For Emergency Use, US FDA May Visit Rather Than Inspect COVID-19 Vaccine Manufacturing Sites

Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel